At a glance
ClinicalIndex Comparison Record- ✓Healthy surgically sterile or postmenopausal females and sterile males
- ✓BMI between 18 and 32 kg/m², inclusive
- ✕Known allergies to abemaciclib, metformin, iodine, iohexol, or related compounds
- ✕Regular use of drugs of abuse or positive urinary drug screen
- ✕HIV, hepatitis B, or hepatitis C seropositivity
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Abemaciclib on Metformin Pharmacokinetics and Iohexol Clearance
In Brief
A Phase 1 clinical trial evaluating Abemaciclib, Metformin, and 2 other interventions for Healthy. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This study will look at how a single dose of abemaciclib will impact the body's ability to get rid of two other drugs, metformin and iohexol. In addition, this study will evaluate the effect of a single dose of abemaciclib on kidney function by measuring blood and urine markers. Side effects will also be documented. Each participant will complete four study periods. During each study period, participants will stay in the clinical research unit for nine days and eight nights. The study will last approximately 10 weeks, not including screening. Screening is required within 28 days prior to the start of the study. This study is for research purposes only and is not intended to treat any medical condition.
Study Details
Timeline
Interventions
Administered orally
Administered orally
Administered intravenously (IV)
Administered orally